Psoriasis and atopic dermatitis are chronic inflammatory disease that account for a
significant amount of patients in most dermatological practices. Topical corticosteroid
agents are often prescribed for treatment of both these conditions, especially when they are
localized rather than wide spread. The development of resistance to treatment is termed
tachyphylaxis. Poor adherence, rather than down regulation of receptors, may be the primary
cause of tachyphylaxis to topical corticosteroids. The primary objective of the study is to
determine, under conditions designed to assure good adherence, whether topical 0.25%
desoximetasone spray improves clinical outcomes in patients who have resistant inflammatory
skin disease defined by failure of previous topical steroid treatment.